Medrio offers an integrated eClinical software platform with a fully hosted EDC system. Our revolutionary CloudEDC™ technology features an easy-to-use drag-and-drop interface, allowing study managers to build their studies in days instead of months without requiring any programming. Medrio's new mobile suite, mSource, supports both event-based and subject-based workflows, offline data entry, and Patient Reported Outcomes (PRO). Although Medrio has extensive experience in all study phases, our m1 application leads the way in early-phase and Phase I trials, with over 500 Phase I trials to date. Medrio costs up to 75% less than traditional EDC solutions.
Veeva Vault Clinical Suite the industry's first cloud platform that combines CDMS - including EDC, coding, CTMS, eTMF and study start-up to deliver the most comprehensive suite of clinical cloud applications. For the first time, life sciences companies can unify clinical operations and data management on a single platform to create a single source of truth, streamline end-to-end processes, and help sponsors, CROs, and sites improve how they work together throughout the clinical trial process.
IBM® Clinical Development is a unified cloud-based data management platform with an advanced electronic data capture (EDC) system that can help reduce the time and cost of clinical trials and help life sciences bring therapies to market faster to benefit patients.
The platform features solutions that cover the entire study – from startup to submission. With IBM Clinical Development, you can gather, organize, analyze and report data for any type, size or phase of trial anywhere in the world.
Oracle Health Sciences - Collect and deliver higher-quality data faster through advanced data capture and query management, real-time visibility to data, standards-based, integrated workflows, and security best practices.
LLX biostatisticians and statistical programmers provide comprehensive biostatistics and statistical programming services to support clinical, pre-clinical and patient-reported outcomes for pharmaceutical, medical devices and biotech companies.